Related Experiment Video
Updated: Aug 5, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Intelligent Genetic Decoding System Based on Nucleic Acid Isothermal Amplification for Non-Small Cell Lung Cancer
Xiaonan Liu1,2, Jiaxing Zhang2, Kai Hua2
1College of Forensic Medicine, Shanxi Medical University, Taiyuan 030001, China.
Abstract:
Non-small cell lung cancer (NSCLC) is a major cause of cancer-related deaths around the world. Targeting the sensitized epidermal growth factor receptor (EGFR) caused by gene mutation through the tyrosine kinase inhibitor is an effective therapeutic strategy for NSCLC. Hence, the individualized therapeutic strategy has highlighted the demand for a simple, fast, and intelligent strategy for the genetic decoding of EGFR to cater to the popularization of precision medicine. In this research, a one-pot assay for EGFR identification is established by combining a loop-mediated isothermal amplification and amplification refractory mutation system. By optimizing the component and condition of the nucleic acid amplification system, a sensitive and specific distinguishability is achieved for tracing target variant (60 copies, 0.1%) identification under a strong interferential background within 40 min. Moreover, complex operation and time-consuming data processing, as well as the aerosol contamination, are avoided owing to the whole process for intelligent genetic decoding being performed in a sealed tube. As a demonstration, L858R, the primary point mutation for the sensitization of EGFR, has been accurately decoded using this assay with highly heterogeneous cancerous tissue. In addition, this method can be easily extended for other genetic information decoding using a tailor-made primer set. Thus, we propose that this straightforward strategy may serve as a promising tool for NSCLC diagnosis in clinical practice.
Insights
A novel one-pot assay rapidly decodes epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). This method enables precise genetic identification for personalized NSCLC treatment, advancing precision medicine.
Area of Science:
- Molecular Biology
- Oncology
- Biotechnology
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally.
- Targeting mutated epidermal growth factor receptor (EGFR) with tyrosine kinase inhibitors is a key NSCLC therapy.
- Precision medicine necessitates rapid and intelligent genetic testing for EGFR mutations.
Purpose of the Study:
- To develop a simple, fast, and intelligent assay for EGFR genetic decoding.
- To facilitate the popularization of precision medicine in NSCLC treatment.
- To provide a tool for accurate EGFR mutation identification in clinical settings.
Main Methods:
- A one-pot assay combining loop-mediated isothermal amplification and amplification refractory mutation system.
- Optimization of nucleic acid amplification components and conditions.
- Intelligent genetic decoding performed within a sealed tube to avoid contamination and complex processing.
Main Results:
- Achieved sensitive and specific identification of target variants (down to 60 copies, 0.1%) within 40 minutes, even with strong background interference.
- Accurately decoded the L858R EGFR mutation in highly heterogeneous cancerous tissue.
- Demonstrated the method's potential for extension to other genetic information decoding with tailor-made primers.
Conclusions:
- The developed one-pot assay offers a straightforward strategy for intelligent EGFR genetic decoding.
- This method overcomes limitations of complex operations and time-consuming data processing.
- The assay shows promise as a valuable tool for NSCLC diagnosis and personalized treatment in clinical practice.
